Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.98 |
| ▸ | HTR2A | P28223 | 7/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.98 |
| ▸ | HRH1 | P35367 | 7/20 | 0.98 |
| ▸ | DRD3 | P35462 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | TP53 | P04637 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.98 |
| ▸ | HTR1A | P08908 | 6/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.98 |
| ▸ | HTR2C | P28335 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL29369439 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL14126977 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL18429 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL29358207 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL1041250 | 0.98 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL2506559 | 0.98 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL28086447 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL5307579 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL10891828 | 0.92 | MAPT (0.90) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| SCHEMBL13485632 | 0.92 | MAPT (0.86) | DRD2MAPTMAPK1ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2710 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| US-10874537-B2 | Intragastric volume-occupying device and method for fabricating same | OBALON THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| CN-110167909-A | Allotropic form of sodium benzoate and application thereof | 心悦生医股份有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-108348557-A | Compositions containing tannins and uses thereof | 心悦生医股份有限公司 | 2018-07-31 | — | — | CN | claimed |
| US-9938576-B1 | Materials and methods for determining metabolizer status in humans | OHIO STATE INNOVATION FOUNDATION (US) | 2018-04-10 | — | — | US | claimed |
| EP-3178470-A1 | ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS | Vitux Group AS (NO) | 2017-06-14 | — | — | EP | claimed |
| EP-3108245-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | Henkin, Robert I. (US) | 2016-12-28 | — | — | EP | claimed |
| CN-106233141-A | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell | 罗伯特·I·汉金 | 2016-12-14 | — | — | CN | claimed |
| WO-2015126944-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | HENKIN ROBERT I (US) | 2015-08-27 | — | — | WO | claimed |
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARM INC (US) | 2015-08-20 | — | — | US | claimed |
| EP-1353649-A2 | PERSONAL MEDICATION DISPENSING CARD | Bassinson, Oscar M. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030175354-A1 | Antiemetic, anti-motion sustained release drug delivery system | L.A.M. PHARMACEUTICAL CORPORATION (CA) | 2003-09-18 | — | — | US | claimed |
| WO-2003009829-A2 | ANTIEMETIC, ANTI-MOTION SUSTAINED RELEASE DRUG DELIVERY SYSTEM | L.A.M. PHARMACEUTICAL CORPORATION (CA) | 2003-02-06 | — | — | WO | claimed |
| WO-2003005998-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT OF MODULATING CHOLINERGIC FUNCTION | PFIZER PRODUCTS INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20030008892-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| US-20020172712-A1 | Antiemetic, anti-motion sustained release drug delivery system | GLYCOBIOSCIENCES INC. (CA) | 2002-11-21 | — | — | US | claimed |
| US-20020125164-A1 | Personal medical dispensing card | BASSINSON OSCAR M (US) | 2002-09-12 | — | — | US | claimed |
| WO-2002049571-A2 | PERSONAL MEDICATION DISPENSING CARD | BASSINSON OSCAR M (US) | 2002-06-27 | — | — | WO | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |